Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study

Journal of Medical Virology

Volumn 70, Issue 4, 2003, Pages 553-561

  Yeo, Winnie ^a   Chan, Paul K S ^a   Hui, Pun ^a   Ho, Wing M ^a   Lam, Kwok C ^a   Kwan, Wing H ^a   Zhong, Sheng ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Breast cancer; Chemotherapy; Hepatitis B virus reactivation

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHOTREXATE; VIRUS DNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DNA DETERMINATION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LIVER FUNCTION; PATIENT MONITORING; RISK FACTOR; SEROPREVALENCE; SIDE EFFECT; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; VIRUS ACTIVATION;

HEPATITIS B VIRUS;

EID: 0038384409     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10430     Document Type: Article

References (38)

1. Ahmed A, Keeffe EB. 1999. Lamivudine therapy in chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 94:249-251.
2. Al-Taie OH, Mork H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M. 1999. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann Hematol 78:247-249.
3. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. 1999. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81:69-74.
4. Bird GL, Smith H, Portmann B, Alexander GJ, Williams R. 1989. Acute liver decompensation on withdrawal of cytotoxic and immunosuppressive therapy in hepatitis B carriers. Q J Med 73:895-902.
5. Bonadonna G, Valagussa A, Moliterni A, et al. 1995. Adjuvant cyclophosphamide, and fluorouracil in node-positive breast cancer. The results of 20 years follow-up. N Engl J Med 332:901-906.
6. Borg FT, Smorenburg S, De Man RA, Rietbroek RC, Chamuleau RAFM, Jones EA. 1998, Recovery from life-threatening corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 43:2267-2270.
7. Chan SW, McOmish F, Holmes EC, Dow B, Peutherer JF, Follett E, et al. 1992. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 73: 1131-1141.
8. Cheng AL. 1996. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma [letter]. Blood 87:1202.
9. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. 1998. Successful treatment oflamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma. Ann Oncol 9:385-387.
10. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. 1993. Trends in cancer incidence and mortality. International Agency for Research on Cancer/Oxford, UK: Oxford University Press.
11. Creavan PJ, Muhich E. 1997. The clinical toxicity of anti-cancer drugs and its prediction. Semin Oncol 4:147-163.
12. Fisher B, Brown AM, Dimitrov N, et al. 1990. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant breast and Bowel Project B-15. J Clin Oncol 8:1483-1496.
13. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ, Bagshawe KD. 1975. Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2:528-530.
14. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829.
15. Hong Kong Hospital Authority. 1998. Cancer incidence and mortality in Hong Kong 1993-1994. Hong Kong Cancer Registry.
16. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. 1982. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447-449
17. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura U, Kodama F, Shimano S, et al. 1997. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 8:107-109.
18. Lau JY, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D. 1989. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 73:911-917.
19. Lau GKK, Liang R, Wu PC, et al. 1998. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 287:359-368.
20. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd O, Chiu EKW. 1990. Hepatitis B infection in patients with lymphomas. Hematol Oncol 8:261-270.
21. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. 1987. Acute exacerbation in chronic type of B hepatitis: comparison between HBeAg and antibody positive patients. Hepatology 7:20-23.
22. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. 1991. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188.
23. Ma B, Yeo W, Hui P, Ho WM, Johnson PJ. 2002. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer - a retrospective review of Chinese patients and comparison with a historic Western series. Radiother Oncol 62:185-189.
24. Maruyama T, Iino S, Koike K, Yasuda K, Milich DR. 1993. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 105:1141-1151.
25. Nair PV, Tong MJ, Stevenson D, Roskamp D, Boone C. 1986. A pilot study on the effects of prednisone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis B. Hepatology 6:1319-1324.
26. Nokamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. 1996. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 78:2210-2215.
27. Ohtsu T, Sai T, Oka Y, Sugai Y, Tobinai K. 1991. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematological malignancies. Jpn J Clin Oncol 21:360-365.
28. Perry MC. 1992. Hepatotoxicity of chemotherapeutic agents. In: Perry MC, editor. The chemotherapy source book. Baltimore, MD: Williams & Wilkins. p 635-647.
29. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. 1990. Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65:878-884.
30. Soh LT, Ang PT, Sng I, Chua EJ, Ong YW. 1992. Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy. Eur J Cancer 28A:1338-1339.
31. Steinberg JL, Yeo W, Zhong S, Chan JYH, Tam JS, Chan PKS, Leung NWY, Johnson PJ. 2000. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/ core mutations may play an important role. J Med Virol 60:249-255.
32. Thung SN, Gerber MA, Klion F, Gilbert H. 1985. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier. Arch Intern Med 145:1313-1314.
33. Webster GJM, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Amlot PL, Williams R, Vergani D, Duskieko GM, Bertoletti A. 2000. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32:1117-1124.
34. Wong GC, Tan P, Goh YT, Ng HS, Lee LH. 1996. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 25:500-503.
35. Yeo W, Steinberg JL, Tam JS, Chan PKS, Leung NWY, Lam KC, Mok TSK, Johnson PJ. 1999. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 59:263-269.
36. Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NWY, Zee B, Johnson PJ. 2000a. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307.
37. Yeo W, Zhong S, Chan PKS, Ho WM, Wong HTM, Chan ASK, Johnson PJ. 2000b. Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepatol 7:448-458.
38. Yeo W, Chan PKS, Chan HLY, Mo FKF, Johnson PJ, 2001. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65:473-477.